Clinical Trial: A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Share this article:

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer


Sponsor and Collaborators

University of Pittsburgh
National Cancer Institute (NCI)

Contact
Athanassios Argiris, MD
(412) 623-4083
argirisae@upmc.edu

Rita Johnson, RN
(412) 547-5871
johnsonr1@upmc.edu

United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109-0848
Principal Investigator: Francis P Worden, MD

United States, Ohio
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Principal Investigator: Panayiotis Savvides, MD, PhD, MPH

United States, Pennsylvania
UPMC / UPMC Cancer Centers Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Jamie Haggerty
Principal Investigator: Athanassios Argiris, MD

United States, Texas
University of Texas MD Anderson Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Merrill s Kies, MD

Principal Investigator
Athanassios Argiris, MD
ECOG

Clinical Trials.gov Identifier

NCT00409565
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs